Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

919 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.
Lam CSP, Køber L, Kuwahara K, Lund LH, Mark PB, Mellbin LG, Schou M, Ely Pizzato P, Gabrielsen A, Gasparyan SB, Ghiretti A, Hartleib-Geschwindner J, Housler GJ, Fanti P, Leonsson-Zachrisson M, McMurray JJV, Solomon SD; MIRACLE Study Investigators. Lam CSP, et al. Eur J Heart Fail. 2024 May 23. doi: 10.1002/ejhf.3294. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38783712
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
Lassen MCH, Ostrominski JW, Inzucchi SE, Claggett BL, Kulac I, Jhund P, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Desai AS, Petersson M, Langkilde AM, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M. Lassen MCH, et al. Among authors: lam csp. Eur J Heart Fail. 2024 May 15. doi: 10.1002/ejhf.3269. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38745498
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis.
Ostrominski JW, Claggett BL, Miao ZM, Mc Causland FR, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Bomfim Wirtz A, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Ostrominski JW, et al. Among authors: lam csp. J Am Coll Cardiol. 2024 May 9:S0735-1097(24)07204-8. doi: 10.1016/j.jacc.2024.05.005. Online ahead of print. J Am Coll Cardiol. 2024. PMID: 38744407 No abstract available.
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay-Flurrie J, McMurray JJV, Solomon SD. Vaduganathan M, et al. Among authors: lam csp. Eur J Heart Fail. 2024 May 14. doi: 10.1002/ejhf.3253. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38742248
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial.
Arrigo M, Davison B, Edwards C, Adamo M, Ambrosy AP, Barros M, Biegus J, Celutkiene J, Čerlinskaitė-Bajorė K, Chioncel O, Cohen-Solal A, Damasceno A, Diaz R, Filippatos G, Gayat E, Kimmoun A, Lam CSP, Metra M, Novosadova M, Pagnesi M, Pang PS, Ponikowski P, Saidu H, Sliwa K, Takagi K, Ter Maaten JM, Tomasoni D, Voors AA, Cotter G, Mebazaa A. Arrigo M, et al. Among authors: lam csp. Am Heart J. 2024 May 11:S0002-8703(24)00106-6. doi: 10.1016/j.ahj.2024.04.019. Online ahead of print. Am Heart J. 2024. PMID: 38740532 Free article.
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to US Adults with Heart Failure.
Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Ostrominski JW, et al. Among authors: lam csp. J Card Fail. 2024 May 11:S1071-9164(24)00156-8. doi: 10.1016/j.cardfail.2024.04.015. Online ahead of print. J Card Fail. 2024. PMID: 38740173 No abstract available.
Titration of Medications after Acute Heart Failure is Safe, Tolerated, and Effective Regardless of Risk.
Ambrosy AP, Chang AJ, Davison B, Voors A, Cohen-Solal A, Damasceno A, Kimmoun A, Lam CSP, Edwards C, Tomasoni D, Gayat E, Filippatos G, Saidu H, Biegus J, Celutkiene J, Ter Maaten JM, Čerlinskaitė-Bajorė K, Sliwa K, Takagi K, Metra M, Novosadova M, Barros M, Adamo M, Pagnesi M, Arrigo M, Chioncel O, Diaz R, Pang PS, Ponikowski P, Cotter G, Mebazaa A. Ambrosy AP, et al. Among authors: lam csp. JACC Heart Fail. 2024 Apr 30:S2213-1779(24)00337-8. doi: 10.1016/j.jchf.2024.04.017. Online ahead of print. JACC Heart Fail. 2024. PMID: 38739123
919 results